Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Does My District Need a Mobile Stroke Unit?
NEJM 385:971-981,1043, Lees, K.R., 2021
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
Complications from "Stem Cell Tourism" in Neurology
Ann Neurol 88:661-668, Julian, K.,et al, 2020
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Cost-Effectiveness of Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
Neurol 86:1053-1059, Aronsson, M.,et al, 2016
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke
Stroke 46:2591-2598, Ganesalingam, J.,et al, 2015
The Cost-Effectiveness of Telestroke in the Treatment of Acute Ischemic Stroke
Neurol 77:1590-1598, Nelson, R.E.,et al, 2011
Impact of Late Diagnosis and Treatment on Life Expectancy in People with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study
BMJ 343:d6016,d6015, May, M.,et al, 2011
Effect of Weekend Compared With Weekday Stroke Admission on Thrombolytic Use, In-Hospital Mortality, Discharge Disposition, Hospital Charges, and Length of Stay in the Nationwide Inpatient Sample Database, 2002 to 2007
Stroke 41:2323-2328, Hoh,B.L.,et al, 2010
Comparative Analysis of Therapeutic Options Used for Myasthenia Gravis
Ann Neurol 68:797-805, Mandawat,A.,et al, 2010
Estimated Cost Savings of Increased Use of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in Canada
Storke 38:1952-1955,1732, Yip,T.R. &Demaerschalk,B.M., 2007